FDA has permitted marketing of ClonoSEQ assay, a next generation sequencing-based test for minimal residual disease in patients with acute lymphoblastic leukemia or multiple myeloma.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
